Ativo Circulante Alterar Data
AbbVie USD 37.48B 3.81B 2026-09
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
Agios Pharmaceuticals USD 752.1M 34.43M 2026-09
ALKERMES USD 1.58B 57.83M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.36B 598M 2026-09
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Cytokinetics USD 1.19B 21.34M 2026-09
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Exelixis USD 1.32B 70.8M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Halozyme Therapeutics USD 1.85B 913.71M 2026-09
Incyte USD 5.52B 505.2M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Prothena USD 273.86M 18.15M 2026-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Repligen USD 1.24B 41.43M 2026-09
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sarepta Therapeutics USD 2.27B 49.06M 2026-09
Teva Pharmaceutical Industries USD 14.6B 842M 2026-09
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09